We've found
13,253
archived clinical trials in
Arthritis
We've found
13,253
archived clinical trials in
Arthritis
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)
Updated: 3/20/2018
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
A Rheumatoid Arthritis Study in Participants
Updated: 3/24/2018
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)
Status: Enrolling
Updated: 3/24/2018
Click here to add this to my saved trials